Clinical Trial Update: Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia [Phase 3]

View source ↗

Summary

Phase 3 trial NK-104-CR for primary hyperlipidemia or mixed dyslipidemia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hyperlipidemia

Drugs mentioned

• NK-104-CR

Snippet

Sponsor: Kowa Research Institute, Inc. | Conditions: Hyperlipidemia, Dyslipidemia | Phase 3 | Status: WITHDRAWN